ATHIRA 0201~A randomized, placebo controlled study of ATH-1017 treatment in patients with mild to moderate Alzheimer’s Disease.
Disease/Condition: Alzheimer’s disease
Enrollment Opens: 11/18/2020
Enrollment Closes: TBD
This is a clinical trial evaluating the safety and efficacy of ATH-1017 treatment in patients with mild to moderate Alzheimer’s Disease. This compound (ATH-1017) is a potent agonist of the HGF/MET systems and potentially works to reduce neuroinflammation, enhance synaptic plasticity, and promote neuronal functioning in the brains of those experiencing Alzheimer’s Disease of other types of dementia.
Study ID: ATHIRA ALZ 0201
To Enroll: Please call (503) 228-2273 (CARE) to schedule free memory lost testing and evaluation. Or contact http://www.summitresearchnetwork.com for additional informaton.
Posted by: Summit Headlands LLC | http://www.summitresearchnetwork.com